|
|
| Line 1: |
Line 1: |
| {{Drugbox|
| |
| |IUPAC_name =
| |
| | image=Amoxapine.svg
| |
| | width=150
| |
| | CAS_number=14028-44-5
| |
| | ATC_prefix=N06
| |
| | ATC_suffix=AA17
| |
| | PubChem=2170
| |
| | DrugBank=APRD00142
| |
| | | C=17 | H=16 | Cl=1 | N=3 | O=1
| |
| | molecular_weight = 313.781
| |
| | bioavailability= ?
| |
| | metabolism = Hepatic ([[cytochrome P450|cytochrome P450 system]])
| |
| | elimination_half-life= 8-10 hours (30 hours for major metabolites)
| |
| | excretion = Renal
| |
| | pregnancy_US = C
| |
| | legal_US = Rx-only
| |
| | routes_of_administration= Oral
| |
| }}
| |
| <!-- Commented out because image was deleted: [[Image:AsendinAd.png|thumb|300px|left|Advertisement, 1989.]] -->
| |
| '''Amoxapine''' (brand-names '''Asendin'''®, '''Asendis'''®, '''Defanyl'''®, '''Demolox'''®, '''Moxadil'''®) is a [[tricyclic antidepressant]] of the [[dibenzoxazepine]] class. It is used in the treatment of [[clinical depression|depression]], [[panic disorder]]s and [[bipolar disorder]].
| |
|
| |
|
| Amoxapine is a strong reuptake inhibitor of [[norepinephrine]] and weak reuptake inhibitor of [[serotonin]]. One of its major metabolites, [[7-hydroxyamoxapine]], has a [[dopamine]] receptor blocking effect.
| |
|
| |
| == See also ==
| |
|
| |
| * [[Loxapine]]
| |
|
| |
| ==References==
| |
| * Mosby Year-Book, Inc. (1995). ''Physician's GenRx: The Complete Drug Reference (5th Ed.)''. Riverside, CT: Denniston Publishing Co.
| |
| * Palfai, T. & Jankiewicz, H. (1997). ''Drugs and Human Behavior (2nd Ed.)''. Madison, WI: Brown & Benchmark.
| |
| * Hedges, D. & Burchfield, C. (2006). ''Mind, Brain, and Drug: An Introduction to Psychopharmacology.'' Boston, MA: Pearson.
| |
|
| |
| {{Antidepressants}}
| |
|
| |
| [[Category:Norepinephrine reuptake inhibitors]]
| |
| [[Category:Tricyclic antidepressants]]
| |
|
| |
|
| |
| {{psychoactive-stub}}
| |
|
| |
| [[fr:Amoxapine]]
| |
| [[ja:アモキサピン]]
| |
| {{WikiDoc Help Menu}}
| |